Method of normalising functional responsiveness of cardiovascular system in arterial hypertension

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to cardiology, and concerns normalising the functional responsiveness of cardiovascular system in arterial hypertension. That is ensured by estimating the condition of functional responsiveness of the CVS in psychoemotional load by recording systolic, diastolic, average dynamic pressure and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after load by formula: FRI=(BPav.dyn. x HR)100 (standard units). When observing the FRI gain by 20 standard units and more, losartan is prescribed in dosage 50 mg in the morning once a day and lacidipine in dosage 2 mg in the morning once a day for at least 2 months.

EFFECT: complex of drug-induced therapy combined with empirically prescribed treatment length provides normalisation of functional responsiveness of the CVS in the given group of the patients due to potentiation of therapeutic effect of the used drugs.

2 ex

 

The invention relates to medicine in the field of cardiology and can be used in therapeutic departments of clinics and hospitals. Analogues of the method of normalization of the functional reactivity of the cardiovascular system with arterial hypertension (AH) does not exist.

The aim of the invention is to increase the efficiency of correction of the functional reactivity of the cardiovascular system in hypertension.

The essence of the proposed method of correction of the functional activity of the cardiovascular system is to increase the tolerance of patients with hypertension to emotional stress and increase functional reactivity of cardiac-vascular system in the execution of their metered emotional load and reducing the risk of cardiovascular complications during emotional stress, measured after holding dosed emotional load with the ever increasing speed for 18-20 minutes with every minute registration parameters of Central hemodynamics: arterial systolic pressure (SBP), diastolic blood pressure (Add), arterial pressure medium dynamic (AD cf. Dean) and heart rate (HR), determine the value of indicator functional reactivity (FIU), which is the product of HELL is renego dynamic on heart rate, calculate the relative increment values FIU when performing load compared with the value at rest and largest values FIU assess the type of functional reactivity of the cardiovascular system: when the FIU is more than 20 usled reactivity assessed as hyperfunctional (with AG), the FIU is less than 10 usled response to the load estimate as Hypo-functional and, when values of the FIU from 10 to 20 usled type functional reactivity assessed as normal. Time psychoemotional load no more than 20 minutes. To normalize the indicator functional reactivity in patients with arterial hypertension used a combination of losartan and lacidipine for at least 2 months.

The inventive method is carried out as follows. The value of the FIU is determined by Lebedeva OD, Radziejewski S.A., Bugaeva S.A. Method of assessment of the functional reactivity of the cardiovascular system EN 2207044. The patient is seated in front of the screen. The patient on the left shoulder impose cuff for measuring blood pressure systolic blood pressure diastolic arterial pressure medium dynamic and heart rate prior to loading and during loading. The patient offer two sets of 4 letters: ANA is and RLOG, of which he must choose to remember one. After registration of the hemodynamic parameters within 3 minutes and the memory (30) of the selected set of letters begin conducting psycho-emotional loads, namely, that the subject pressing notes scattered letters from the selected set of progress on the monitor screen square frames situated in a random sequence the letters of the alphabet. The speed of advancement of the frames in the series of letters in the process of conducting samples increases with 3 letters 1 at the beginning of the load up to 6 characters 1 to from 6 min load, and this provides a gradual vrabatavaemomu patient. Errors in elevation of letters from a selected set of auditory signals, for which the subject may be oriented in the proper execution of the load and try to adjust its execution. After the load calculates the average value of the BPA, Add, Map. Dean and heart rate in the periods: prior to loading and during loading. HELL the average dynamic calculated by the formula: HELL srcin=Add+[0,42(SBP-ADC)].

HELL the average dynamic is a complex resultant of all variables HELL. The test with emotional stress in healthy individuals the HELL the average dynamic changes slightly, and the heart rate usually increases. According to studies of HC is the increase in heart rate and HELL leads to increased demand of oxygen and increase its energy costs. In pathology, for example, when AG vessels in a state of spasm, unable to provide the required increased amount of oxygen, which can increase hypoxia, incoming cerebral circulation, etc.

On the basis of the data used to calculate the functional reactivity, which allows an integrative measure of the increase in hemodynamic load on the heart and, consequently, the risk of developing cardiovascular complications, defined as follows:

FIU=(Adsin×HR)*/100(used).

The increment values FIU during the transition from rest to execution of the load determines the index:

FIU=PFR-PFR,

where the FIU is the dierence between the values of the FIU before and during exercise;

PFR - averaged value of the index before load;

PFR - averaged value of the index under load.

The relative increment values FIU assess the type of functional reactivity of the cardiovascular system: if the value is *, then divide by 100 to obtain conventional units (used - the double digits).

When you study in the dynamics of treatment the patient was given to remember a different set of letters in order to prevent addiction.

When the increment values after conducting dosed emotional load FIU from 10 to 20 s.the D. functional type of reactivity is assessed as normal. When the FIU to load more than 20 usled type functional reactivity assessed as hyperfunctional. In this case the patient AH, you must assign at least 2 months, the combination of losartan 50 mg in the morning of 1 times and lacidipine 2 mg in the morning 1 times.

Timely and effective correction of the FIU in patients with hypertension will allow in the short term to normalize the functional reactivity of the cardiovascular system that will reduce these patients the period of temporary disability, renders prophylactic action against strokes and heart attacks, reduce the number of outputs on disability and reduce mortality among patients with hypertension.

Example 1. Examined the patient C., 40 years old, with hypertension within 1 year. The BPA before the load was equal to 118 mm Hg, Add - 80 mm Hg, Adsin - 96,8 mm Hg, heart rate is 70 beats per 1 minute, the FIU was equal (9670)/100=67 used the BPA when conducting load increased to 133 mm Hg, Add - up to 85 mm Hg, HELL Srdan to 105 mm Hg, heart rate of 80 beats per 1 minute FIU equal (10580)/100=84 used When conducting psycho-emotional load was obtained increment values FIU 67 used to 84 used, that is, 17 usled that lies within the bounds of normal values increment FIU when conducting psycho-emotional activity in healthy individuals and does not require correction FIU.

Example 2. Examined patient A., 52 years old, suffering is th AG 8 years. In the study of hemodynamics in the initial state before conducting psycho-emotional loads the BPA was equal to 140 mm Hg, Add - on 90 mm Hg, Adsin - 111 mm Hg, heart rate of 75 beats per 1 minute FIU before psychoemotional load was equal (11175)/100 - 83 used When conducting psycho-emotional loads BPA increased to 166 mm Hg, Add - 100 mm Hg, Adsin to 128 mm Hg, heart rate is 90 beats per 1 minute, the FIU is increased to (12890)/100=115 used, i.e. the increment on PPV load or what is the same - FIU was 32 used (83 used to 115 used), which can be considered as a manifestation of hyperthyroidism cardiovascular system. The patient is assigned to a combination of losartan 50 mg in the morning and lacidipine 2 mg in the morning. After 2 months of treatment, the magnitude of the FIU fell before the load compared to the same before the treatment: the BPA - up to 130 mm Hg, Add - up to 85 mm Hg, Adsin to 104 mm Hg, heart rate up to 67 beats per 1 minute, FIU - up to 70 used When performing load marked decrease compared with the condition before treatment the increase in value of the BPA - up to 145 mm Hg, Add - up to 90 mm Hg, Adsin up to 113 mm Hg, heart rate of 80 beats per 1 minute, FIU - 90 used, that is marked increment values FIU 20 used (before treatment - 32 used), which may be indicative of increased tolerance of the cardiovascular system to psycho-emotional stress, about the reduction of an overactive heart is but your cardiovascular system and, therefore, the economization of cardiac activity.

As a result of application of the proposed method of correction of functional reactivity of the cardiovascular system in patients with arterial hypertension is achieved normalization of the functional reactivity of the cardiovascular system for dosed psycho-emotional stress, which allows you to use the way for the normalization of the tolerance of patients with hypertension to psycho-emotional stress, which can reduce the degree of hemodynamic load when exposed to stress, reducing the risk of development of psycho-emotional loads adverse cardiovascular reactions (angina, myocardial infarction, ischemic, and others).

The method of normalization of the functional reactivity of the cardiovascular system (CVS) with arterial hypertension, including assessment of functional reactivity SSS during emotional load, which record systolic, diastolic, srednetehnicheskoe pressure, based on these data, determine the rate of functional reactivity (FIU) before and after exercise, using the formula: FIU=(Adsin.·Heart rate (HR)100 (used), and when the FIU is more than 20 usled enter the combination of losartan 50 mg 1 in the morning every day and lacidipine 2 mg in the morning 1 time per day for at least 2 who nazev.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention refers to compounds of the formula (I) and pharmaceutically acceptable salts, where R1-R7 mean the same as provided in the invention description and claim. Compounds of the formula (I) are specific inhibitors of 11b-HSD1. They can be applied in treatment and/or prevention of diseases caused by dysfunctions related to 11b-HSD1 enzyme, particularly in treatment and/or prevention of metabolic diseases, obesity, dyslipidemia, hypertension and/or diabetes, especially diabetes type "П". Additionally subject matter includes pharmaceutical composition for treatment and/or prevention of the said diseases.

EFFECT: improved efficiency of derivatives.

21 cl, 1 tbl, 146 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology, and relates normalisation of cardio-vascular system functional reactivity in case of arterial hypertension with metabolic syndrome. For this purpose evaluation of CVS functional reactivity state under psychoemotional load is performed by registration of systolic diastolic, mean dynamic pressure and heart beat rate (HBR). On the basis of said data functional reactivity index (FRI) is determined before and after the load by the formula: FRI=(APav.dyn.x HBR)100 (conv.unit). If FRI is higher than 20 conv.units complex treatment including individually composed hypocaloric diet, which is calculated by formula taking into account sex, age and body weight, reasonably dosed static and dynamic physical loads, as well as introduction of valsartan 80 mg 1 time in the morning and pioglitazone 30 mg 1 time in the morning during not less than 3 months.

EFFECT: said complex of medicinal and non-medicinal therapy in combination with empirically selected treatment duration ensure normalisation of CVS functional reactivity in said group of patients due to potentiation of therapeutic effect of certain components of medicinal complex.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology, and concerns normalising functional reactivity of cardiovascular system (CVS) in arterial hypertension, impaired glucose tolerance and abdominal obesity. That is ensured by estimating the condition of functional reactivity of the CVS in psychoemotional load by recording systolic, diastolic, average dynamic pressure and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after load by formula: FRI=(BPav.dyn. × HR)×100(standard units). The post-load FRI increment more than by 20 standard units requires the integrated treatment including individually prescribed hypocaloric diet calculated by considering sex, age and body weight, rationally graduated static and dynamic physical activity, administration of irbesartan 150 mg once a day in the morning and pioglitazone 30 mg once a day in the morning at least within 4 months.

EFFECT: complex drug-induced and drug-free therapy combined with empirically prescribed treatment length provides normalisation of functional reactance of the CVS in the given group of patients due to potentiation of therapeutic effect of separate components of an individual care.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely cardiology, and concerns normalising functional reactivity of cardiovascular system (CVS) in arterial hypertension and impaired glucose tolerance. That is ensured by estimating the condition of functional reactivity of the CVS in psychoemotional load by recording systolic, diastolic, average dynamic pressure (BPav.dyn.) and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after stress by formula: FRI=(BPav.dyn. x HR)/100(standard units). The post-load value PFR increased more than by 20 standard units requires the complex therapy including graduated static and dynamic physical activity, and introduction of irbesartan in a dose 150 mg in the morning once a day and pioglitazone in a dose 30 mg in the morning once a day at least within 4 months.

EFFECT: complex of drug-induced therapy combined with physical activity and empirically prescribed treatment length provides normalisation of functional reactivityof the CVS in the given group of the patients due to potentiation of therapeutic effect of the used drugs.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to cardiology, and concerns normalising the functional responsiveness of cardiovascular system in arterial hypertension and dyslipidemia. That is ensured by estimation of the functional responsiveness of CVS while psychoemotional stress to record systolic, diastolic, average dynamic blood pressure (BPav.dyn.) and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after stress by formula: FRI=(BPav.dyn. × HR)/100 (standard units). The after-stress FRI increment by more than 20 standard units require the integrated therapy involving swimming in a swimming pool for at least 20 minutes a day, morning hygienic and therapeutic gymnastics within a day, graduated physical exercises within a day and administration of losartan in a dose 50 mg once a day in the morning. The therapeutic course is at least 4 months.

EFFECT: integrated pharmacotherapy and drug-free modalities combined with empirically prescribed treatment length provides normalised functional responsiveness of CVS in the given group of patients due to potentiation of therapeutic effect of separate components of the integrated treatment.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to new crystalline modifications of N-α-(2,4,6-triisopropylphenylsulphonyl)-3-hydroxyamidino-(L)-phenylalanine-4-ethoxycarbonyl piperazide and/or its salts. Such crystalline modifications have high stability particularly at low hygroscopicity compared to known amorphous forms of the compound.

EFFECT: invention relates to a method of obtaining such new crystalline modifications, to pharmaceutical compositions containing these new crystalline modifications and their use as an anti-tumour agent.

26 cl, 7 tbl, 13 ex, 20 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology, and concerns normalising functional reactivity of cardiovascular system (CVS) at arterial hypertension and abdominal obesity. To that end, the state of CVS functional reactivity at psychoemotional stress is assessed by recording systolic, diastolic and average dynamic blood pressure (BP av.dyn) and heart rate (HR). These data serve as the basis for determining functional reactivity index (FRI) prior to and after the stress, according to the following formula: FRI = (BP av.dyn. × heat rate)/100 (conv. un.). If FRI value after stress rises by more than 20 conventional units, complex therapy is implemented including individual hypocaloric diet calculated by a formula considering sex and age, sensibly graded static and dynamic physical exercise as well as administration of irbesartan in a dose of 50 mg once a day, in the morning, over at least 4 months.

EFFECT: complex of drug and non-drug treatment combined with empirically chosen course duration ensures normalisation of CVS functional reactivity among the specified group of patients due to potentiation of certain components of the therapeutic complex.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology, and concerns normalising functional reactivity of cardiovascular system (CVS) at arterial hypertension and abdominal obesity. To that end, the state of CVS functional reactivity at psychoemotional stress is assessed by recording systolic, diastolic and average dynamic blood pressure (BP av.dyn) and heart rate (HR). These data serve as the basis for determining functional reactivity index (FRI) prior to and after the stress, according to the following formula: FRI = (BP av.dyn. × heat rate)/100 (conv. un.). If FRI value after stress rises by more than 20 conventional units, complex therapy is implemented including individual hypocaloric diet calculated by a formula considering sex and age, sensibly graded static and dynamic physical exercise as well as administration of losartane in a dose of 50 mg once a day, in the morning, over at least 4 months.

EFFECT: complex of drug and non-drug treatment combined with empirically chosen course duration ensures normalisation of CVS functional reactivity among the specified group of patients due to potentiation of certain components of the therapeutic complex.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology, and concerns normalisation of cardiovascular system (CVS) functional reactivity among patients suffering from arterial hypertension at the stage of recovery form cerebral circulation disorder without pareses or paralyses. To that end, the state of CVS functional reactivity at psychoemotional stress is assessed by recording systolic, diastolic and average dynamic blood pressure. These data serve as the basis for determining functional reactivity index (FRI) prior to and after the stress, according to the following formula: FRI = (BP av.dyn. × heat rate)100 (conv. un.). If FRI value after stress rises by more than 20 conventional units, telmisartan and labetalole are administered in doses of 40 mg per day and 200 mg twice a day respectively.

EFFECT: method normalises functional reactivity of cardiovascular system and increases tolerance to psychoemotional stresses at the specified group of patients during a 2 month course of therapy.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel crystalline form of perindopril of formula I: . Also proposed are methods for synthesis of amorphous and crystalline perindopril using starting substance in form of stereospecific amino acid, N-[(S)-carbethoxy-1-butyl]-(S)-alanine, which is protected by a trimethylsilyl group and converted to reactive acid chloride using thionyl chloride or its complex with 1-H-benzotriazole (1:1), which reacts with (2S, 3aS, 7aS)-octahydroindole-2-carboxylic acid, having a protected carboxy group. The invention also relates to a pharmaceutical composition based on the said crystalline form of perindopril.

EFFECT: novel form of perindopril is obtained, which can be used in medicine for treating cardiovascular diseases.

8 cl, 4 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology, and concerns normalising functional reactivity of cardiovascular system (CVS) in arterial hypertension, impaired glucose tolerance and abdominal obesity. That is ensured by estimating the condition of functional reactivity of the CVS in psychoemotional load by recording systolic, diastolic, average dynamic pressure and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after load by formula: FRI=(BPav.dyn. × HR)×100(standard units). The post-load FRI increment more than by 20 standard units requires the integrated treatment including individually prescribed hypocaloric diet calculated by considering sex, age and body weight, rationally graduated static and dynamic physical activity, administration of irbesartan 150 mg once a day in the morning and pioglitazone 30 mg once a day in the morning at least within 4 months.

EFFECT: complex drug-induced and drug-free therapy combined with empirically prescribed treatment length provides normalisation of functional reactance of the CVS in the given group of patients due to potentiation of therapeutic effect of separate components of an individual care.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to cardiology, and concerns normalising the functional responsiveness of cardiovascular system in arterial hypertension and dyslipidemia. That is ensured by estimation of the functional responsiveness of CVS while psychoemotional stress to record systolic, diastolic, average dynamic blood pressure (BPav.dyn.) and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after stress by formula: FRI=(BPav.dyn. × HR)/100 (standard units). The after-stress FRI increment by more than 20 standard units require the integrated therapy involving swimming in a swimming pool for at least 20 minutes a day, morning hygienic and therapeutic gymnastics within a day, graduated physical exercises within a day and administration of losartan in a dose 50 mg once a day in the morning. The therapeutic course is at least 4 months.

EFFECT: integrated pharmacotherapy and drug-free modalities combined with empirically prescribed treatment length provides normalised functional responsiveness of CVS in the given group of patients due to potentiation of therapeutic effect of separate components of the integrated treatment.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology, and concerns normalising functional reactivity of cardiovascular system (CVS) at arterial hypertension and abdominal obesity. To that end, the state of CVS functional reactivity at psychoemotional stress is assessed by recording systolic, diastolic and average dynamic blood pressure (BP av.dyn) and heart rate (HR). These data serve as the basis for determining functional reactivity index (FRI) prior to and after the stress, according to the following formula: FRI = (BP av.dyn. × heat rate)/100 (conv. un.). If FRI value after stress rises by more than 20 conventional units, complex therapy is implemented including individual hypocaloric diet calculated by a formula considering sex and age, sensibly graded static and dynamic physical exercise as well as administration of irbesartan in a dose of 50 mg once a day, in the morning, over at least 4 months.

EFFECT: complex of drug and non-drug treatment combined with empirically chosen course duration ensures normalisation of CVS functional reactivity among the specified group of patients due to potentiation of certain components of the therapeutic complex.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology, and concerns normalising functional reactivity of cardiovascular system (CVS) at arterial hypertension and abdominal obesity. To that end, the state of CVS functional reactivity at psychoemotional stress is assessed by recording systolic, diastolic and average dynamic blood pressure (BP av.dyn) and heart rate (HR). These data serve as the basis for determining functional reactivity index (FRI) prior to and after the stress, according to the following formula: FRI = (BP av.dyn. × heat rate)/100 (conv. un.). If FRI value after stress rises by more than 20 conventional units, complex therapy is implemented including individual hypocaloric diet calculated by a formula considering sex and age, sensibly graded static and dynamic physical exercise as well as administration of losartane in a dose of 50 mg once a day, in the morning, over at least 4 months.

EFFECT: complex of drug and non-drug treatment combined with empirically chosen course duration ensures normalisation of CVS functional reactivity among the specified group of patients due to potentiation of certain components of the therapeutic complex.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a free base (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)- ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine in crystalline form, having a powder X-ray diffraction pattern with peaks at diffraction angles (2θ) 15.7±0.1, 17.3±0.1 and 19.7±0.1. The invention also relates to a pharmaceutical composition, to methods of treating cancer in mammals, as well as to a method of treating abnormal cell growth in mammals in need of such treatment.

EFFECT: obtaining an novel biologically active compound having the said inhibitory activity.

12 cl, 1 ex, 3 tbl, 2 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound or its salt of formula 1: , where A, E, D, R0, R1-R4 and a assume values given in the formula of invention. The invention also relates to an antioxidant medicinal agent.

EFFECT: effectiveness during treatment of ischemic diseases of organs, during treatment of diseases caused by oxidation cell disorders and when inhibiting disorders of the retina.

4 cl, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula

or

or to their pharmaceutically acceptable salts, where ring A, R2, R3, R4 and X are as defined in the description. The disclosed compounds are useful as 11βHSD1 inhibitor. The invention also relates to a pharmaceutical composition, an agent for treating or preventing pathology related to glucocorticoids, a 11βHSD1 inhibitor containing the disclosed compound or its pharmaceutically acceptable salt, and use of the disclosed compounds.

EFFECT: compounds are highly effective.

40 cl, 48 tbl, 191 ex

FIELD: chemistry.

SUBSTANCE: invention proposes 5-member heterocyclic inhibitors of kinase p38, including kinase p38α and kinase p38β, based on pyrazoles and imidazoles, with the general formula given below , in which ring B is phenyl, and C is a pyrazole or imidazole ring, and the rest of the symbols assume values given in paragraph 1 of the formula of invention.

EFFECT: there are described pharmaceutical compositions containing said compounds, as well as methods of using the compounds and compositions, including a method of treating, preventing or suppressing one or more symptoms of diseases and conditions mediated by kinase p38 which include, but not limited to, inflammatory diseases and conditions.

31 cl, 6 tbl, 175 ex

Pyrazoles // 2381217

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I), where one of R1 and R2 is hydrogen or alkyl, and the other is (CH2)PY, where p=0 or 1, Y is a saturated mono-, bi- or tricyclic 5-10-member cycloalkyl ring optionally substituted with alkyl, or R1 and R2 together with N form a 7-10-member saturated bicyclic ring Z, optionally substituted with halogen, or a 5-7-member monocyclic ring Z, optionally substituted with alkyl, phenyl, phenylalkyl or pyridinyl; R3 is [2,2']bithiophenyl, 1-methylindole, 2,3-dihydrobenzo[1,4]dioxin, benzo[1,3]dioxole, benzothiophene, dibenzofuran, furan, naphthalene, quinoline, thianthrene, thiophene or pyrrole, or biphenyl substituted with halogen, or phenyl optionally substituted with one or more amino, cyano, formyls, halogens, hydroxyl, hydroxymethyls, acyls, acylamino, alkoxy, nitro, trifluoromethoxy, trifluoromethyls, phenoxy or benzyloxy, or R3 is a group, where Ar is phenyl substituted with halogen; and R4 is alkyl; and pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition with inhibitory activity towards the 11β-hydroxysteroid dehydrogenase1 (11(β-HSD1) enzyme.

EFFECT: pyrazole composition is disclosed.

22 cl, 1 tbl, 116 ex

FIELD: medicine.

SUBSTANCE: invention is related to antagonists of serotonin 5-HT6 receptors of common formula 1 and their pharmaceutically acceptable salts and/or hydrates, pharmaceutical compositions, dosage forms and methods of production. Invention also includes new compounds of formula 1.1. In formulae 1 and 1.1 , Ar represents aryl, selected from unnecessarily substituted phenyl or unnecessarily substituted 5-6-member heteroaryl, which contains atom of nitrogen or atom of sulfur and heteroatom; R1 represents atom of hydrogen, unnecessarily substituted C1-C5 alkyl; Ar represents aryl, selected from unnecessarily substituted phenyl or unnecessarily substituted 5-6-member heteroaryl, which contains atom of nitrogen or atom of sulfur as heteroatom; R1 represents atom of hydrogen, which is unnecessarily substituted C1-C5 alkyl; R21,R22, R31, R32 independently from each other represent atom of hydrogen or substituent of aminogroup, selected from unnecessarily substituted C1-C4 alkyl, unnecessarily substituted phenyl, or R31 and R32 together with atom of nitrogen, to which they are bound, create unnecessarily substituted saturated 6-member heterocycle, possibly containing atom of nitrogen in cycle; or R1 together with atom of nitrogen, to which it is bound, and R21 and R22 together with atom of nitrogen, to which they are bound, create substituted pyrimidine cycle. In formula 1.1 R4, R5 and R6 independently from each other represent atom of hydrogen, unnecessarily substituted C1-C3 alkyl or phenyl.

EFFECT: compounds of invention may find application for treatment and prevention of development of conditions and disorders of central nervous system.

13 cl, 11 dwg, 4 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel hexafluoroisopropanol-substituted ether derivatives of formula (I) to their pharmaceutically acceptable salts and to esters which are capable of bonding with LXR-alpha and/or LXR-beta, as well as to pharmaceutical compositions based on said compounds. In formula (I) R1 is hydrogen, lower alkyl or halogen, one of groups R2 and R3 is hydrogen, lower alkyl or halogen, and the second of groups R2 and R3 is -O-CHR4-(CH2)m-(CHR5)n-R6. Values of R4, R5, R6 m and n are given in the formula of invention.

EFFECT: novel compounds have useful biological properties.

22 cl, 4 dwg, 102 ex

Up!